Does atorvastatin interact with her current medication?

AKAnna Keller, 47 · Hypertension, prediabetes, LDL 162 mg/dl · 14 documents, read 16 September 2026

Answered on 16 September 2026

Her current medication: ramipril 5 mg, sertraline 50 mg. Medication 16.09.2026 No clinically relevant interaction with either. Atorvastatin is metabolised by CYP3A4; the interactions that matter are with strong CYP3A4 inhibitors such as clarithromycin, itraconazole and ritonavir, with ciclosporin and gemfibrozil, and with large amounts of grapefruit juice. None is on her list. Eur Heart J

The relevant safety question is the earlier myalgia, not an interaction: start low (10 mg), take it in the evening, document the baseline CK (96 U/l in May) and re-check CK and ALT at eight weeks or earlier if symptoms return. Lab 08.05.2026 Visit 14.03.2024 Eur Heart J If a macrolide is ever prescribed for an infection, pause atorvastatin for the course. Eur Heart J

From the patient record3 of 14 documents

Medication list, 16 September 2026Medication
Laboratory report, 8 May 2026Laboratory
Visit note, simvastatin stopped, 14 March 2024Clinical note

1.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.European Heart Journal. 2020;41:111-188. Mach F, Baigent C, Catapano AL, et al.Guideline
SummaryLDL cholesterol goals by risk category: below 116 mg/dl at low risk, below 100 mg/dl at moderate risk, below 70 mg/dl at high risk, below 55 mg/dl at very high risk. Statins first, ezetimibe second, PCSK9 inhibitors third. Statin interactions run mainly through CYP3A4 (atorvastatin, simvastatin) and OATP1B1; monitoring of ALT and CK is defined.
Source
Issuing body: ESC and European Atherosclerosis Society
Published: January 2020; focused update 2025
Grading system: ESC classes of recommendation I–III, levels of evidence A–C
Scope
Target population: Adults with dyslipidaemia or elevated cardiovascular risk
Scope: Targets, drugs, monitoring, special situations
2.Statin-associated muscle symptoms: impact on statin therapy. European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.European Heart Journal. 2015;36:1012-1022. Stroes ES, Thompson PD, Corsini A, et al.Guideline
SummaryDefines statin-associated muscle symptoms as symmetric proximal muscle pain, weakness or stiffness beginning within weeks to months of a statin start and improving within weeks of withdrawal; CK is usually normal or mildly raised. Management: withdraw, wait for symptoms to resolve, then rechallenge with the same or a different statin at a lower dose or alternate-day dosing; most patients tolerate a second statin. Non-statin therapy for those who cannot.
Source
Issuing body: European Atherosclerosis Society Consensus Panel
Published: May 2015
Grading system: Consensus statement
Scope
Target population: Patients with muscle symptoms on statin therapy
Scope: Definition, assessment, management, rechallenge

What would you like to ask next?

1Create a take-home explaining why she is starting a statin 2Given her history and today's findings, what should I consider next?3Why was her statin stopped?

This is a sample workspace. Click one of the questions. To ask your own questions, request access.

Anna Keller, 47Mosaic